Alpine Immune Sciences Inc Stock News

Checkpoint inhibitors do one thing: release the molecular brake that keeps immune cells from recognizing and targeting tumors. This cancer immunotherapy

Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.

Companies in the news are: SPOT, ALPN, AESE, NEON

Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) * ADC Therapeutics SA (NYSE: ADCT) * Adverum Biotech

Alpine Immune Sciences (NASDAQ:ALPN) and Nabriva Therapeutics (NASDAQ:NBRV) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the stre

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) ADC Therapeutics SA (NYSE:...

Oppenheimer analyst Mark Breidenbach maintained a Buy rating on Alpine Immune Sciences (ALPN – Research Report) today and set a

All three major indexes came back from this morning's losses with marginal gains midday, but investors anxieties over coronavirus and jobless claims linger

In the current session, Alpine Immune Sciences Inc. (NASDAQ: ALPN) is trading at $9.87, after a 102.67% increase. Over the past month, the stock increased by 194.10%, and in the past year, by 123.24%.

Alpine Immune Sciences and AbbVie Announce Option and License Agreement for the Development and Commercialization of ALPN-101